The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Observational Studies Analyzed Like Randomized Experiments: An Application to Postmenopausal Hormone Therapy and Coronary Heart Disease
Open accessAbstract
BACKGROUND: The Women's Health Initiative randomized trial found greater coronary heart disease (CHD) risk in women assigned to estrogen/progestin therapy than in those assigned to placebo. Observational studies had previously suggested reduced CHD risk in hormone users. METHODS: Using data from the observational Nurses' Health Study, we emulated the design and intention-to-treat (ITT) analysis of the randomized trial. The observational study was conceptualized as a sequence of "trials," in which eligible women were classified as initiators or noninitiators of estrogen/progestin therapy. RESULTS: The ITT hazard ratios (HRs) (95% confidence intervals) of CHD for initiators versus noninitiators were 1.42 (0.92-2.20) for the first 2 years, and 0.96 (0.78-1.18) for the entire follow-up. The ITT HRs were 0.84 (0.61-1.14) in women within 10 years of menopause, and 1.12 (0.84-1.48) in the others (P value for interaction = 0.08). These ITT estimates are similar to those from the Women's Health Initiative. Because the ITT approach causes severe treatment misclassification, we also estimated adherence-adjusted effects by inverse probability weighting. The HRs were 1.61 (0.97-2.66) for the first 2 years, and 0.98 (0.66-1.49) for the entire follow-up. The HRs were 0.54 (0.19-1.51) in women within 10 years after menopause, and 1.20 (0.78-1.84) in others (P value for interaction = 0.01). We also present comparisons between these estimates and previously reported Nurses' Health Study estimates. CONCLUSIONS: Our findings suggest that the discrepancies between the Women's Health Initiative and Nurses' Health Study ITT estimates could be largely explained by differences in the distribution of time since menopause and length of follow-up.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Randomized, Controlled Trials, Observational Studies, and the Hierarchy of Research Designs
Concato, J., Shah, N., & Horwitz, R. I. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006223422507 · Cited by 3,563
Miller, R. G. (1981) · Cited by 3,336
A structural approach to selection bias
Hernán, M. A., Hernández-Díaz, S., & Robins, J. M. (2004) · Epidemiology · doi:10.1097/01.ede.0000135174.63482.43 · Cited by 2,844 · cited 1×
“of their estimated probability of remaining uncensored until that month.(16) To estimate “trial”-specific probabilities for each woman, we fit a pooled logistic model for the probability of remaining on the baseline treatment through a given month.”
BackgroundSelf-citationDesign of the Women’s Health Initiative Clinical Trial and Observational Study
(1998) · Controlled Clinical Trials · doi:10.1016/s0197-2456(97)00078-0 · Cited by 2,585
Robins, J. (1986) · Mathematical Modelling · doi:10.1016/0270-0255(86)90088-6 · Cited by 2,451
Self-citationA comparison of observational studies and randomized, controlled trials.
Benson, K., & Hartz, A. J. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006223422506 · Cited by 2,347
Estrogen plus Progestin and the Risk of Coronary Heart Disease
Manson, J. E., Hsia, J., Johnson, K. C., Rossouw, J. E., Assaf, A. R., Lasser, N. L., Trevisan, M., Black, H. R., Heckbert, S. R., Detrano, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030808 · Cited by 2,065 · cited 1×
“6 years).(8,9) The present paper does not address the complex clinical and public health issues related to hormone therapy, including risk-benefit considerations.”
BackgroundSelf-citationPrimary Prevention of Coronary Heart Disease in Women through Diet and Lifestyle
Stampfer, M. J., Hu, F. B., Manson, J. E., Rimm, E. B., & Willett, W. C. (2000) · New England Journal of Medicine · doi:10.1056/nejm200007063430103 · Cited by 1,794
Self-citationEvaluating medication effects outside of clinical trials: new-user designs
Ray, W. A. (2003) · American Journal of Epidemiology · doi:10.1093/aje/kwg231 · Cited by 1,646 · cited 2×
“This exclusion bias may be quantified through simulations,(21) reduced by stratification of the analysis on duration of therapy at baseline,(21) and eliminated by making the start of follow-up coincident with the time of treatment initiation, as discussed by Robins(22,23) and Ray.(24) The approach we present here and…”
MethodPostmenopausal Estrogen and Progestin Use and the Risk of Cardiovascular Disease
Grodstein, F., Stampfer, M. J., Manson, J. E., Colditz, G. A., Willett, W. C., Rosner, B., Speizer, F. E., & Hennekens, C. H. (1996) · New England Journal of Medicine · doi:10.1056/nejm199608153350701 · Cited by 1,305
Self-citation
Cited by
ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions
Sterne, J. A., Hernán, M. A., Reeves, B. C., Savović, J., Berkman, N. D., Viswanathan, M., Henry, D., Altman, D. G., Ansari, M. T., Boutron, I., et al. (2016) · BMJ · doi:10.1136/bmj.i4919 · Cited by 20,329
“18 However, fear that evidence from NRSI may be biased, based on misleading results of some NRSI, 19 20 has led to caution in their use in making judgements about efficacy.”
BackgroundSelf-citationUsing Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available: Table 1.
Hernán, M. A., & Robins, J. M. (2016) · American Journal of Epidemiology · doi:10.1093/aje/kwv254 · Cited by 3,115
Self-citationInterpretation of the evidence for the efficacy and safety of statin therapy
Collins, R., Reith, C., Emberson, J., Armitage, J., Baigent, C., Blackwell, L., Blumenthal, R., Danesh, J., Smith, G. D., DeMets, D., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31357-5 · Cited by 1,857
Hernán, M. A. (2010) · Epidemiology · doi:10.1097/ede.0b013e3181c1ea43 · Cited by 1,370
Self-citationTriangulation in aetiological epidemiology
Lawlor, D. A., Tilling, K., & Davey Smith, G. (2017) · International Journal of Epidemiology · doi:10.1093/ije/dyw314 · Cited by 1,129
Hernán, M. A., Sauer, B. C., Hernández-Díaz, S., Platt, R., & Shrier, I. (2016) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2016.04.014 · Cited by 1,097
Self-citationTarget Trial Emulation: A Framework for Causal Inference From Observational Data
Hernán, M. A., Wang, W., & Leaf, D. E. (2022) · JAMA · doi:10.1001/jama.2022.21383 · Cited by 994
Self-citationKosiborod, M., Cavender, M. A., Fu, A. Z., Wilding, J. P., Khunti, K., Holl, R. W., Norhammar, A., Birkeland, K. I., Jørgensen, M. E., Thuresson, M., et al. (2017) · Circulation · doi:10.1161/circulationaha.117.029190 · Cited by 813
LaCroix, A. Z. (2011) · JAMA · doi:10.1001/jama.2011.382 · Cited by 538
The Use of Propensity Scores to Assess the Generalizability of Results from Randomized Trials
Stuart, E. A., Cole, S. R., Bradshaw, C. P., & Leaf, P. J. (2011) · Journal of the Royal Statistical Society Series A: Statistics in Society · doi:10.1111/j.1467-985x.2010.00673.x · Cited by 524
Shadish, W. R., Clark, M. H., & Steiner, P. M. (2008) · Journal of the American Statistical Association · doi:10.1198/016214508000000733 · Cited by 479
Six Persistent Research Misconceptions
Rothman, K. J. (2014) · Journal of General Internal Medicine · doi:10.1007/s11606-013-2755-z · Cited by 438
PFAS and cancer, a scoping review of the epidemiologic evidence
Steenland, K., & Winquist, A. (2021) · Environmental Research · doi:10.1016/j.envres.2020.110690 · Cited by 426
Attributable Mortality of Ventilator-Associated Pneumonia: A Reappraisal Using Causal Analysis
Bekaert, M., Timsit, J.-F., Vansteelandt, S., Depuydt, P., Vésin, A., Garrouste-Orgeas, M., Decruyenaere, J., Clec'h, C., Azoulay, E., & Benoit, D. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201105-0867oc · Cited by 395
The False-positive to False-negative Ratio in Epidemiologic Studies
Ioannidis, J. P. A., Tarone, R., & McLaughlin, J. K. (2011) · Epidemiology · doi:10.1097/ede.0b013e31821b506e · Cited by 321
When and how can real world data analyses substitute for randomized controlled trials?
Franklin, J. M., & Schneeweiss, S. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.857 · Cited by 316
Avoidable flaws in observational analyses: an application to statins and cancer
Dickerman, B. A., García-Albéniz, X., Logan, R. W., Denaxas, S., & Hernán, M. A. (2019) · Nature Medicine · doi:10.1038/s41591-019-0597-x · Cited by 308
Self-citationStürmer, T., Wyss, R., Glynn, R. J., & Brookhart, M. A. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12197 · Cited by 302
A Review of Generalizability and Transportability
Degtiar, I., & Rose, S. (2023) · Annual Review of Statistics and Its Application · doi:10.1146/annurev-statistics-042522-103837 · Cited by 295
Danaei, G., Rodríguez, L. A. G., Cantero, O. F., Logan, R., & Hernán, M. A. (2013) · Statistical Methods in Medical Research · doi:10.1177/0962280211403603 · Cited by 292
Self-citationBero, L., Chartres, N., Diong, J., Fabbri, A., Ghersi, D., Lam, J., Lau, A., McDonald, S., Mintzes, B., Sutton, P., et al. (2018) · Systematic Reviews · doi:10.1186/s13643-018-0915-2 · Cited by 278
Graphical Depiction of Longitudinal Study Designs in Health Care Databases
Schneeweiss, S., Rassen, J. A., Brown, J. S., Rothman, K. J., Happe, L., Arlett, P., Dal Pan, G., Goettsch, W., Murk, W., & Wang, S. V. (2019) · Annals of Internal Medicine · doi:10.7326/m18-3079 · Cited by 275
Generalizing Study Results: A Potential Outcomes Perspective
Lesko, C. R., Buchanan, A. L., Westreich, D., Edwards, J. K., Hudgens, M. G., & Cole, S. R. (2017) · Epidemiology · doi:10.1097/ede.0000000000000664 · Cited by 269
Danaei, G., Tavakkoli, M., & Hernán, M. A. (2012) · American Journal of Epidemiology · doi:10.1093/aje/kwr301 · Cited by 264
Self-citationA basic study design for expedited safety signal evaluation based on electronic healthcare data
Schneeweiss, S. (2010) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1926 · Cited by 255
The “Efficacy-Effectiveness Gap”: Historical Background and Current Conceptualization
Nordon, C., Karcher, H., Groenwold, R. H. H., Ankarfeldt, M. Z., Pichler, F., Chevrou-Severac, H., Rossignol, M., Abbe, A., & Abenhaim, L. (2016) · Value in Health · doi:10.1016/j.jval.2015.09.2938 · Cited by 177
Is there a role for menopausal hormone therapy in the management of postmenopausal osteoporosis?
Rozenberg, S., Al-Daghri, N., Aubertin-Leheudre, M., Brandi, M.-L., Cano, A., Collins, P., Cooper, C., Genazzani, A. R., Hillard, T., Kanis, J. A., et al. (2020) · Osteoporosis International · doi:10.1007/s00198-020-05497-8 · Cited by 149
Jones, B. E., Ying, J., Stevens, V., Haroldsen, C., He, T., Nevers, M., Christensen, M. A., Nelson, R. E., Stoddard, G. J., Sauer, B. C., et al. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2019.7495 · Cited by 122
Franklin, J. M., Pawar, A., Martin, D., Glynn, R. J., Levenson, M., Temple, R., & Schneeweiss, S. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1633 · Cited by 119
Haber, N., Smith, E. R., Moscoe, E., Andrews, K., Audy, R., Bell, W., Brennan, A. T., Breskin, A., Kane, J. C., Karra, M., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0196346 · Cited by 97
“The summary assessments asked whether the study was likely to approximate hypothetical results from an “ideal” randomized controlled trial which would result in perfectly estimated and generalizable causal effects without practical and ethical constraints [40].”
BackgroundA Structural Description of Biases That Generate Immortal Time
Hernán, M. A., Sterne, J. A. C., Higgins, J. P. T., Shrier, I., & Hernández-Díaz, S. (2025) · Epidemiology · doi:10.1097/ede.0000000000001808 · Cited by 99
Self-citationWinquist, A., Hodge, J. M., Diver, W. R., Rodriguez, J. L., Troeschel, A. N., Daniel, J., & Teras, L. R. (2023) · Environmental Health Perspectives · doi:10.1289/ehp13174 · Cited by 75
Tripathi, A., Liese, A. D., Jerrell, J. M., Zhang, J., Rizvi, A. A., Albrecht, H., & Duffus, W. A. (2014) · Diabetic Medicine · doi:10.1111/dme.12455 · Cited by 74
Taylor, G. M. J., Itani, T., Thomas, K. H., Rai, D., Jones, T., Windmeijer, F., Martin, R. M., Munafò, M. R., Davies, N. M., & Taylor, A. E. (2020) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntz072 · Cited by 68
Vandenbroucke, J., & Pearce, N. (2015) · American Journal of Epidemiology · doi:10.1093/aje/kwv225 · Cited by 67
“Although limiting the analysis to persons followed from first exposure onward solved this problem in 1 study (29), an analysis by duration of exposure (time since first exposure) (28) addressed the problem equally well and showed essentially the same findings (36).”
BackgroundMethodDesign considerations in an active medical product safety monitoring system.
Gagne, J. J., Fireman, B., Ryan, P. B., Maclure, M., Gerhard, T., Toh, S., Rassen, J. A., Nelson, J. C., & Schneeweiss, S. (2012) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.2316 · Cited by 49
Lutsey, P. L., Zakai, N. A., MacLehose, R. F., Norby, F. L., Walker, R. F., Roetker, N. S., Adam, T. J., & Alonso, A. (2019) · British Journal of Haematology · doi:10.1111/bjh.15857 · Cited by 47
Brown, D. M., Hernandez, E. A., Levin, S., De Vaan, M., Kim, M.-O., Lynch, C., Roth, A., & Brewster, A. L. (2022) · Annals of Internal Medicine · doi:10.7326/m22-0074 · Cited by 42
Targeted learning with daily EHR data
Sofrygin, O., Zhu, Z., Schmittdiel, J. A., Adams, A. S., Grant, R. W., van der Laan, M. J., & Neugebauer, R. (2019) · Statistics in Medicine · doi:10.1002/sim.8164 · Cited by 35
“Specifically, the dSL ensemble for each Qk, for all four analytic datasets, is restricted to the following 8 estimators: GBMs with xgboost (3); GLMs with xgboost (1); and regularized GLMs with xgboost (4).”
MethodRajan, K. B., Mcaninch, E. A., Wilson, R. S., Dhana, A., Evans-Lacko, S., & Evans, D. A. (2024) · Neurology · doi:10.1212/wnl.0000000000209168 · Cited by 34
Schwartz, J. D., Di, Q., Requia, W. J., Dominici, F., & Zanobetti, A. (2021) · Epidemiology · doi:10.1097/ede.0000000000001354 · Cited by 17
Couples-based interventions and postpartum contraceptive uptake: a systematic review
Sack, D. E., Peetluk, L. S., & Audet, C. M. (2022) · Contraception · doi:10.1016/j.contraception.2022.05.001 · Cited by 7
Metadata
- Authors
- Hernán, M. A., Alonso, A., Logan, R., Grodstein, F., Michels, K. B., Willett, W. C., Manson, J. E., & Robins, J. M.
- Venue
- Epidemiology
- Published
- 2008-11
- Volume
- 19
- Issue
- 6
- Pages
- 766-779
- ISSN
- 1044-3983 (ISSN-L)
- OpenAlex
- W2062359643
- Cited by
- 818
- References
- 33
- FWCI
- 21.11
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.